Chad M. Robins - 06 Apr 2026 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Reporting relationship: CEO and Chairman, Director
Issuer ticker: ADPT
Reported as of: 06 Apr 2026
Net transaction value: -$1,766,839
SEC form: 4
Accepted by SEC: 08 Apr 2026, 19:51:17 UTC
Prior SEC filing: 13 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Chad M Robins by Kyle Piskel, Attorney-in-Fact

Key filing fact

Chad M. Robins filed Form 4 for Adaptive Biotechnologies Corp (ADPT) on 08 Apr 2026.

Key facts

This page summarizes Chad M. Robins's Form 4 filing for Adaptive Biotechnologies Corp (ADPT).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 08 Apr 2026, 19:51.

Change

Previous filing in this sequence was filed on 13 Mar 2026.
Current net transaction value: -$1,766,839.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001780649 Primary reporting owner

ROBINS CHAD M

Relationship: CEO and Chairman, Director
Address: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVENUE EAST, SEATTLE
Signature: /s/ Chad M Robins by Kyle Piskel, Attorney-in-Fact
Signature date: 08 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADPT transaction

Common Stock

Sale

Transaction value: $1,200,814
Shares: -83,332
Change %: -3.6%
Price: $14.41
Shares after: 2,217,781
Date: 06 Apr 2026
Ownership: Direct
Footnotes: F1, F2

ADPT transaction

Common Stock

Sale

Transaction value: $566,025
Shares: -37,263
Change %: -1.7%
Price: $15.19
Shares after: 2,180,518
Date: 08 Apr 2026
Ownership: Direct
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

Footnote F2

The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.19 to $14.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

Footnote F3

The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.